ST. LOUIS — A Missouri state judge has granted final approval to a $7.25 billion nationwide class-action settlement designed to extinguish tens of thousands of lawsuits alleging that Bayer’s blockbuster weedkiller, Roundup, causes cancer.
The ruling by St. Louis Circuit Judge Timothy Boyer marks a major turning point in the long-running litigation stemming from Bayer’s 2018 acquisition of Monsanto. Characterizing the agreement as fair and reasonable, the judge noted it ranks among the largest mass-tort settlements in U.S. history.

Payout Terms and Structure
Without admitting liability, Bayer will finance the settlement through declining annual payments spanning up to 21 years to cover approximately 65,000 active and future non-Hodgkin lymphoma claims. Under the tiered structure of the agreement, individual payouts will range from $10,000 to $165,000 depending on factors such as age, exposure duration, and diagnosis severity, while plaintiffs’ attorneys are set to receive $600 million from the fund. In approving the deal, Judge Boyer overruled critics who argued individual payouts were too small, warning that further litigation would unnecessarily delay relief for ailing patients.
Lead counsel Christopher Seeger praised the order for delivering long-awaited compensation, while CEO Bill Anderson hailed the decision as a decisive milestone bolstered by a recent favorable U.S. Supreme Court ruling regarding federal pesticide preemption.
Broader Impact and Future Outlook
While Bayer has already committed over $10 billion to prior waves of litigation and altered consumer formulas, the scientific dispute over glyphosate persists between international health agencies and federal regulators. Analysts anticipate potential appeals regarding how the settlement binds future claimants, though the decision provides Bayer a vital path toward resolving its most significant legal overhang.
